Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT125A CAR T Cells for CD5+ Hematopoietic Malignancies
NCT04767308Phase 1Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Mar 2021
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CT125A in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and 2 more, sponsored by Huazhong University of Science and Technology. Primary endpoints: Incidence and types of dose limited toxicities at 28 days and Incidence and severity of adverse events at 2 years. Status: unknown.
02
Drugs
CT125A
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04767308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767308.